{"id":"arm-closed-enoxaparin","safety":{"commonSideEffects":[{"rate":"1-3%","effect":"Bleeding"},{"rate":"<1%","effect":"Thrombocytopenia"},{"rate":"5-10%","effect":"Injection site hematoma"},{"rate":"1-3%","effect":"Elevated transaminases"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Enoxaparin works by potentiating antithrombin III, a natural anticoagulant, to inactivate clotting factors Xa and IIa in the coagulation cascade. This prevents thrombin generation and fibrin formation, reducing the risk of thromboembolism. It is administered subcutaneously and has more predictable pharmacokinetics than unfractionated heparin.","oneSentence":"Enoxaparin is a low-molecular-weight heparin that inhibits blood clotting by enhancing the activity of antithrombin III against factors Xa and IIa.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:44:08.231Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Venous thromboembolism prophylaxis"},{"name":"Acute coronary syndrome"},{"name":"Deep vein thrombosis treatment"},{"name":"Pulmonary embolism treatment"}]},"trialDetails":[{"nctId":"NCT04483960","phase":"PHASE3","title":"Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Melbourne","startDate":"2020-07-28","conditions":"SARS-CoV-2 Infection (COVID-19)","enrollment":2200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"(Arm Closed) Enoxaparin","genericName":"(Arm Closed) Enoxaparin","companyName":"University of Melbourne","companyId":"university-of-melbourne","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Enoxaparin is a low-molecular-weight heparin that inhibits blood clotting by enhancing the activity of antithrombin III against factors Xa and IIa. Used for Venous thromboembolism prophylaxis, Acute coronary syndrome, Deep vein thrombosis treatment.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}